Type of study | BE tolerant | Resolution of egg allergy | |
---|---|---|---|
Sicherer et al. [40] (n = 113) | Observational without OFC | 38 % by 6 years | After 6 years: |
71 % in those who reported BE tolerance | |||
45 % in those not ingesting BE | |||
57 % in those who reported BE reactivity | |||
Des Roches et al. [30] | Prospective with OFC | 73 % | |
Lemon-Mule et al. [19] (n = 91) and Leonard et al. [31] (n = 79; follow-on study) | Prospective with OFC | 70 % initially, | 53 % of those ingesting BE (followed for median 37.8 months) |
89 % by end of follow-on study | 28 % of control group (followed for median 67.3 months) | ||
Clark et al. [24] (n = 95) | Longitudinal with OFC | 66 % | N/A |
Lieberman et al. [25] (n = 100) | Retrospective with OFC | 66 % | N/A |
Cortot et al. [26] (n = 52) | Retrospective with OFC | 83 % | N/A |
Turner et al. [18] (n = 236) | Prospective with OFC | 64 % | N/A |
Tan et al. [27] (n = 143) | Prospective with OFC | 63 % | N/A |
Bartnikas et al. [28] (n = 169) | Retrospective with OFC | 84 % | N/A |
Turner et al. [29] (n = 186) | Retrospective with OFC | 66 % | N/A |
Peters et al. [37] (n = 158) | Prospective with OFC or by report | 80 % by OFC | By age 2 years of age: |
72 % by report | 49 % of those ingesting BE after OFC at 1 year | ||
74 % of those ingesting BE by report at 1 year | |||
13 % of those with positive BE OFC at 1 year |